Antigen Loss Variants: Catching Hold of Escaping Foes

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Cancer immunotherapy has advanced significantly since the 1990s, with immunotherapies becoming standard treatments for certain cancers.
• Tumor cells express specific antigens, enabling targeted immune responses, but antigen loss can lead to treatment resistance and relapse.
• Antigen loss variants, such as CD19/CD20 loss in leukemia and lineage switching in MLL-rearranged leukemia, are well-documented challenges in cancer therapy.

Purpose of the Study:

• To review the occurrence of antigen loss variants in leukemia.
• To discuss therapeutic strategies for managing antigen loss variants.
• To present a novel dual-targeting immunoligand approach for MLL-associated leukemia.

Main Methods:

• Literature review on antigen loss variants in leukemia.
• Discussion of current and novel therapeutic strategies.
• Presentation of a dual-targeting immunoligand concept for NK cell-mediated targeting of antigen loss variants.

Main Results:

• Antigen loss is a common mechanism for immune escape and therapy resistance in leukemia.
• Existing immunotherapies often fail to address antigen loss variants.
• Dual-targeting immunoligands show potential for effective targeting of antigen loss variants in MLL-associated leukemia.

Conclusions:

• Targeting antigen loss variants is crucial for improving leukemia treatment outcomes.
• Simultaneous targeting of multiple tumor antigens holds promise for eradicating tumors and preventing relapse.
• Novel immunotherapies, including dual-targeting strategies, are essential for overcoming treatment resistance in leukemia.